| 08/04/26 | 07:00:09 | 8 Apr 2026 | | Granted U.S. Patent from PTSD Discovery Programme |
| 31/03/26 | 07:00:14 | 31 Mar 2026 | | Granted U.S. Patent from PTSD Discovery Programme |
| 10/03/26 | 07:00:10 | 10 Mar 2026 | | SVN-114 selected for PTSD discovery programme |
| 28/01/26 | 07:00:09 | 28 Jan 2026 | | Expansion of SVN-015 into depression |
| 07/01/26 | 07:00:07 | 7 Jan 2026 | | US Patent allowance for PTSD discovery programme |
| 22/12/25 | 07:00:04 | 22 Dec 2025 | | Research and Development Update – Q4 2025 |
| 03/12/25 | 07:00:11 | 3 Dec 2025 | | SVN-015 accepted into US NIDA funded programme |
| 31/10/25 | 15:59:40 | 31 Oct 2025 | | Total Voting Rights |
| 31/10/25 | 07:00:12 | 31 Oct 2025 | | Corporate Structure Update and Issue of Options |
| 27/10/25 | 07:00:13 | 27 Oct 2025 | | Appoints global biopharma leader Paul Carter |
| 16/10/25 | 07:00:10 | 16 Oct 2025 | | Raises £1.25 Million to Accelerate Programmes |
| 30/09/25 | 07:00:20 | 30 Sept 2025 | | Half-year Report |
| 28/08/25 | 07:00:03 | 28 Aug 2025 | | Solvonis secures exclusive CNS collaboration |
| 13/08/25 | 15:03:11 | 13 Aug 2025 | | Media Coverage: Small Cap Idea profile |
| 12/08/25 | 07:00:06 | 12 Aug 2025 | | SVN-SDN-14 PTSD - Positive pre-clinical results |
| 31/07/25 | 16:30:00 | 31 Jul 2025 | | Total Voting Rights |
| 22/07/25 | 07:00:07 | 22 Jul 2025 | | Translational Bridging Studies |
| 18/07/25 | 11:03:39 | 18 Jul 2025 | | Exercise of warrants |
| 14/07/25 | 07:00:14 | 14 Jul 2025 | | Solvonis Chair to speak at Lucid Capital Markets |
| 11/07/25 | 07:00:06 | 11 Jul 2025 | | £1m subscription to accelerate AI drug discovery |
| 08/07/25 | 07:00:09 | 8 Jul 2025 | | Holding(s) in Company |
| 27/06/25 | 14:38:50 | 27 Jun 2025 | | AGM Statement |
| 27/06/25 | 08:54:41 | 27 Jun 2025 | | Holding(s) in Company |
| 26/06/25 | 10:21:21 | 26 Jun 2025 | | Initiation of Research Coverage |
| 23/06/25 | 07:00:08 | 23 Jun 2025 | | Allowance of U.S. patent covering AI-supported CNS |
| 11/06/25 | 07:30:00 | 11 Jun 2025 | | Initiation of AI supported CNS drug discovery |
| 05/06/25 | 07:00:13 | 5 Jun 2025 | | Synthesis of development candidate for SVN-SDN-014 |
| 03/06/25 | 16:30:00 | 3 Jun 2025 | | Notice of Annual General Meeting |
| 03/06/25 | 07:00:05 | 3 Jun 2025 | | Appointment of Prof. David Nutt as CSO |
| 02/06/25 | 11:58:16 | 2 Jun 2025 | | Holding(s) in Company |
| 30/05/25 | 17:00:01 | 30 May 2025 | | Total Voting Rights |
| 29/05/25 | 15:11:25 | 29 May 2025 | | Holding(s) in Company |
| 29/05/25 | 12:02:57 | 29 May 2025 | | Holding(s) in Company |
| 29/05/25 | 10:30:00 | 29 May 2025 | | Holding(s) in Company |
| 29/05/25 | 07:00:10 | 29 May 2025 | | Presentation at Mello2025 |
| 28/05/25 | 07:30:00 | 28 May 2025 | | Holding(s) in Company |
| 28/05/25 | 07:00:05 | 28 May 2025 | | Completion of the acquisition of Awakn |
| 21/05/25 | 15:24:02 | 21 May 2025 | | Publication of a Prospectus |
| 16/05/25 | 07:31:04 | 16 May 2025 | | Result of placing |
| 15/05/25 | 16:53:16 | 15 May 2025 | | Proposed equity fundraising via ABB |
| 28/04/25 | 11:30:00 | 28 Apr 2025 | | Result of General Meeting |
| 23/04/25 | 07:00:07 | 23 Apr 2025 | | Proposed acquisition of Awakn approved |
| 16/04/25 | 07:00:06 | 16 Apr 2025 | | Final Results for the year ended 31 December 2024 |
| 10/04/25 | 14:00:01 | 10 Apr 2025 | | Posting of Circular and Notice of General Meeting |
| 07/04/25 | 07:00:10 | 7 Apr 2025 | | Holding(s) in Company |
| 04/04/25 | 07:00:01 | 4 Apr 2025 | | Engagement of PharmaVentures |
| 26/03/25 | 07:00:02 | 26 Mar 2025 | | Positive progress on European Patent Application |
| 18/03/25 | 07:00:04 | 18 Mar 2025 | | Update on AWKN-SDN-14 programme |
| 11/03/25 | 09:00:01 | 11 Mar 2025 | | Holding(s) in Company |
| 11/03/25 | 07:00:12 | 11 Mar 2025 | | Appointment of Non-Executive Director |
